




HCV-908: A New Approach to Hepatitis C



Hepatitis C
virus




©2001 James A. Perkins

Life Sciences Alliance:
Meisha Bynoe
Lihong Jiang
Sarah Murphy
Michele Rhee

HCV-908: Current Landscape



Reasons to Move Forward with Phase III



Unique Drug Compound



Open Space in the Market



Profitability




Marketing Potential

HCV-908: A Unique Drug Compound



HCV Genome



HCV Polymerase

HCV-908: Unmet Needs in the Market



Genotype 1

Side effects


Failure to cure

**3,778,000
uncured HCV-
positive patients
in the US**


HCV-908: Increasing Market



Population Growth of HCV-Diagnosed Patients in the US




HCV-908: Growth Potential of the Market




HCV-908: Profitability



- 20 year time frame
- Increasing patient population
- Marketing costs as a percentage of sales



HCV-908: Marketing Approach



HCV-908: Forging a New Path

